L
Lizhu Lin
Researcher at Guangzhou Medical University
Publications - 5
Citations - 458
Lizhu Lin is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Clinical endpoint & Tolerability. The author has an hindex of 5, co-authored 5 publications receiving 176 citations.
Papers
More filters
Journal ArticleDOI
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Jing Huang,Jianming Xu,Chen Yun,Wu Zhuang,Yiping Zhang,Zhendong Chen,Jia Chen,Helong Zhang,Zuoxing Niu,Qingxia Fan,Lizhu Lin,Kangsheng Gu,Ying Liu,Yi Ba,Zhanhui Miao,Xiaodong Jiang,Ming Zeng,Jianhua Chen,Zhichao Fu,Lu Gan,Jun Wang,Xianbao Zhan,Tianshu Liu,Zhiping Li,Lin Shen,Yongqian Shu,Tao Zhang,Qing Yang,Jianjun Zou,Suxia Luo,Feng Peng,Gang Wu,Nong Xu,Lin Zhao,Dong Ma,Shukui Qin,Wei Ren,Enxiao Li,H. Lu,Yueyin Pan,Jianping Xiong,Ying Yuan,Yuxian Bai,Lei Chen,Yi Hu,Li Zhang,Yong Gao +46 more
TL;DR: Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile.
Journal ArticleDOI
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
Shukui Qin,Jin Li,Liwei Wang,Jianming Xu,Ying Cheng,Yuxian Bai,Wei Li,Nong Xu,Lizhu Lin,Qiong Wu,Yunfeng Li,Jianwei Yang,Hongming Pan,Xuenong Ouyang,Wensheng Qiu,Kaichun Wu,Jianping Xiong,Guanghai Dai,Houjie Liang,Chunhong Hu,Zhang Jun,Min Tao,Qiang Yao,Junyuan Wang,Jiongjie Chen,S. Peter Eggleton,Tianshu Liu +26 more
TL;DR: The TAILOR study met all of its objectives and relevant clinical end points, confirming cetuximab in combination with FOLFOX as an effective standard-of-care first-line treatment regimen for patients with RAS wt mCRC.
Journal ArticleDOI
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
Rui-Hua Xu,Lin Shen,Ke-Ming Wang,Gang Wu,Chunmei Shi,Ke-Feng Ding,Lizhu Lin,Jinwan Wang,Jianping Xiong,Changping Wu,Jin Li,Yunpeng Liu,Dong Wang,Yi Ba,Jueping Feng,Yuxian Bai,Jing-Wang Bi,Li-Wen Ma,Jian Lei,Qing Yang,Hao Yu +20 more
TL;DR: Famitinib prolonged PFS in refractory mCRC patients with acceptable tolerability in a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Journal ArticleDOI
A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer.
Rui-Hua Xu,Lin Shen,Ke-Ming Wang,Gang Wu,Chunmei Shi,Kefeng Ding,Lizhu Lin,Jinwan Wang,Jianping Xiong,Changping Wu,Jin Li,Yunpeng Liu,Dong Wang,Yi Ba,Jueping Feng,Yuxian Bai,Jing-Wang Bi,Liwen Ma,Jian Lei,Hao Yu +19 more
TL;DR: This phase II study was designed to evaluate the efficacy and safety of famitinib in the treatment of advanced colorectal cancer and the primary endpoint was progression-free survival.
Journal ArticleDOI
A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens.
Yan Huang,Li Zhang,Jianji Pan,Guoqing Hu,Wu Gang,Jian ping Xiong,Chaosu Hu,Lizhu Lin,Hao Yu,Haoyuan Jiang +9 more
TL;DR: Famitinib is an oral, small molecular multiple tyrosine-kinase inhibitor (TKI), targeting stem cell growth factor receptor (c-Kit), platelet derived growth factor receptors (PDGFR) and stem cell immune cell reprograming (C-Kit).